Announcement
Public Announcement-Open Offer 14 Oct - VC Corporate Advisors Private Limited has Submitted to the Exchange a copy of offer opening public announcement cum corrigendum to the detailed public statement to …
Source: Nse
Onyx Biotec Ltd. (ONYX)
SME CapPharma stocks · SME cap · NSE
Onyx Biotec Ltd. operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals20 Oct 2026 · screener
Latest result15 May, 04:21 am IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags24 Apr 2026
Coverage12/14 · 86%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
70BullishSMA20 -8.3% / mo · MACD + · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 50
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
ONYXD candles · FIT view+12.1%Latest close ₹37.00 on 2026-10-21
Bar
-0.7%
RSI
44
MACD hist
0.11
52W pos
50%
2026-10-21O ₹37.25H ₹37.25L ₹37.00C ₹37.00Vol 4,000 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
ONYXNifty PharmaNifty 500
- ONYX
- +0.0%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- +6.5 pp
Chart stats
21 Oct 2026- From 52W high
- -27.5%
- 52W range position
- 48%
- ATR (14)
- 3.3%
- Volume vs 20D
- 0.13x
- Avg traded value
- ₹0.1 Cr
- 20D price channel
- ₹35.5 - ₹39.5
₹51
₹24.2 - ₹51
₹1.2
Latest completed session
20-session average
35.0% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Verify management risk first
Do not let cheap valuation override weak Trust or governance evidence.
U-Score
Legacy · OVERVALUED15
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad0
Revenue +16.8% · PAT -66.0% YoY
Technical
Bullish70
Price trend and sector-relative-strength timing.
Valuation
Legacy model—
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence49
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 31 Mar 2026
Bad · 0/100PAT -66% YoY · margin compression · Rev +17% YoY
Filed 31 Mar 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹34.9 Cr | +16.8% | +0.8% |
| EBITDA | ₹2.5 Cr | NDF | +160.6% |
| Operating margin | 7.0% | NDF | +430 bps |
| PAT | ₹0.7 Cr | -66.0% | NDF |
| PAT margin | 2.0% | NDF | +458 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- —
- P/B
- 1.22
- EV/EBITDA
- 12.80
- Market Cap
- 67.50Cr
Profitability
- ROE
- -0.38%
- ROCE
- 1.15%
- ROA
- -0.22%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 8.00%
- EPS 5Y
- 8.00%
- Revenue 3Y
- 21.00%
- EPS 3Y
- 6.00%
Balance Sheet
- Debt/Equity
- 0.27
- Interest Coverage
- 2.80×
- Altman Z
- 2.63
- Book Value
- 30.60
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 1/5
- OCF
- -1.49 Cr
- EPS TTM
- -0.12
Shareholding
- Promoter Hold
- 65.10%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 51%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 34.9+0.8% vs prev
Net Profit
₹ CrLatest: 0.7+176.7% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term uptrend intact. RSI 44.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 falling (~9.0% over last month) — short-term momentum negative.
- RSI(14) at 44 — falling, no extreme reading.
- MACD above signal but histogram contracting — bullish momentum cooling.
- 25% off 52W high · 53% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
53
RS percentile
Stage 3 Topping
1M return
-2.6%
3M return
-3.3%
6M return
+12.1%
1Y return
-23.3%
RS 1D
+2
RS 20D
+7
Sector rank
#1
Industry rank
#9
Stage evidence
- 24.5% below the 52-week closing high after prior strength.
- The 30-week proxy has stalled (+0.6% over 20 sessions).
- Price has not yet confirmed a full Stage 4 downtrend.
50-DMA
price below
200-DMA
price above
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
233 observations
21 Oct 2026Value 90.87+0.26%
RS vs Nifty 50091
Valuation & peers
U-Score 15 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 15 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
OVERVALUED
Fundamental score breakdown
U band · OVERVALUEDValuation6/30
Growth7/25
Quality0/20
Balance Sheet9/15
Cash Flow0/10
Piotroski
3/9 (+1)
Penalties
-8
Raw sum
15
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
15/100 · legacy band OVERVALUED
Positive drivers
- Balance sheet contributes 9/15 to the score.
- Growth contributes 7/25 to the score.
- Valuation contributes 6/30 to the score.
Main drags
- Penalty bucket subtracts 8 points.
- Quality is weaker at 0/20; verify the latest quarterly trend.
- Cash flow is weaker at 0/10; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
—
PB
1.2
EV/EBITDA
12.8
ROE
-0.4%
ROCE
1.1%
FCF Yield
—
Debt/Equity
0.3
MoS
—
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
15
Previous: 15
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
—
No stored baseline yet
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
15
15
15
15
15
15
15
15
15
15
15
15
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
—
Growth-justified P/E
19.6
Growth-justified Value
—
— MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
DHANSA
SME
Dhansa Labs Limited
Pharmaceuticals
match 163
22
12.2
5.6%
-52%
OVERVALUED
ZENITHDRUG
SME
Zenith Drugs Ltd.
Pharmaceuticals
match 162
75
6.9
26.3%
+84%
DEEP VALUE
ARISTO
SME
Aristo Bio-Tech and Lifescience Ltd.
Pharmaceuticals
match 162
77
8.5
17.6%
+81%
DEEP VALUE
MONOPHARMA
SME
Mono Pharmacare Ltd.
Pharmaceuticals
match 160
18
21.6
2.3%
-408%
OVERVALUED
SOTAC
SME
Sotac Pharmaceuticals Ltd.
Pharmaceuticals
match 160
55
17.5
10.1%
+62%
FAIR VALUE
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Onyx Biotec Ltd. operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
49Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 6th percentile of the scored universe and 4th percentile within Pharma. Main check: cash conversion is weak at 28/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
1 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
6th percentile
overall median 67 · Pharma: 4th pctile, median 70 · SME: 6th pctile, median 64
Evidence depth
Financial-only
1 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Needs extra due diligence; demand valuation comfort and recent improvement.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
28
weak · profit to cash conversion
Balance sheet
73
acceptable · leverage and solvency
Discipline
30
weak · capital discipline
Results
31
weak · quarterly consistency
Trust positives
- ▸Promoter holding is 65.1%.
- ▸Promoter pledge is zero.
Trust risks
- ▸Operating cash flow is negative at ₹-1 Cr.
- ▸2 latest quarters had PAT decline worse than 25% YoY.
- ▸Only 1 years of positive FCF.
- ▸ROCE is low at 1.1%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Onyx Biotec Ltd.
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Annual reportSep 2026
Sep 2026 · Copy of Newspaper Publication 7 Sep - 21st AGM on September 28, 2026 via VC/OAVM; e-voting details and annual report dispatched.
Source: Nse
Announcement
Corrigendum 4 Aug - VC Corporate Advisors Private Limited has Submitted to the Exchange a copy of corrigendum to the public announcement dated July24, 2026 for the attention of …
Source: Nse
Announcement
Updates 31 Jul - Announcement text unreadable; key details cannot be determined.
Source: Nse
Announcement
Public Announcement-Open Offer 24 Jul - VC Corporate Advisors Pvt Ltd has submitted to the Exchange a copy of Public announcement under Regulations 3(1) and 4 Read with Regulations 13, 14 …
Source: Nse
Annual reportMar 2026
Mar 2026 · Annual Report 2026
Source: Nse
Annual reportMar 2025
Mar 2025 · Annual Report 2025
Source: Nse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.